INS and type 2 diabetes mellitus: There is a need for long-term studies of CGM use in those with T2DM on basal-only and no-insulin regimens characterizing the longitudinal outcomes of potential reductions in hospitalizations and macro- and microvascular complications to help guide cost-benefit analysis for access expansion.